Insider Buying: KindlyMD (NASDAQ:NAKA) CEO Acquires 104,833 Shares of Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey purchased 104,833 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The stock was purchased at an average price of $4.84 per share, for a total transaction of $507,391.72. Following the acquisition, the chief executive officer owned 3,120,361 shares of the company’s stock, valued at $15,102,547.24. The trade was a 3.48% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

KindlyMD Stock Down 1.6%

KindlyMD stock opened at $5.40 on Thursday. The business’s 50-day simple moving average is $8.31 and its 200 day simple moving average is $13.24. The stock has a market cap of $93.96 million, a price-to-earnings ratio of -0.13 and a beta of 17.12. KindlyMD, Inc. has a 12-month low of $4.50 and a 12-month high of $1,120.00.

KindlyMD (NASDAQ:NAKA) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($15.20) earnings per share (EPS) for the quarter. The firm had revenue of $2.68 million during the quarter. KindlyMD had a negative net margin of 7,397.12% and a negative return on equity of 81.32%. As a group, sell-side analysts expect that KindlyMD, Inc. will post -16.8 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on NAKA shares. Weiss Ratings upgraded KindlyMD from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Wall Street Zen upgraded KindlyMD to a “sell” rating in a report on Saturday, May 23rd. Maxim Group decreased their price target on KindlyMD from $60.00 to $30.00 and set a “buy” rating on the stock in a report on Monday, April 6th. TD Cowen began coverage on KindlyMD in a research note on Friday, April 10th. They issued a “buy” rating and a $40.00 target price on the stock. Finally, B. Riley Financial cut their target price on KindlyMD from $40.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, February 23rd. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $30.00.

Hedge Funds Weigh In On KindlyMD

Several hedge funds have recently added to or reduced their stakes in NAKA. Sagespring Wealth Partners LLC acquired a new position in KindlyMD in the fourth quarter valued at about $28,000. SG Americas Securities LLC acquired a new stake in shares of KindlyMD during the fourth quarter worth about $61,000. Virtu Financial LLC acquired a new stake in shares of KindlyMD during the fourth quarter worth about $151,000. J. Derek Lewis & Associates Inc. acquired a new stake in shares of KindlyMD during the fourth quarter worth about $167,000. Finally, Truist Financial Corp acquired a new stake in shares of KindlyMD during the fourth quarter worth about $176,000.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.